‘Racialized Myths,’ Medical Exploitation, and Dire Results
By Kylie Marsh and Herbert L. White,
The Charlotte Post
| 08. 31. 2024
"Office of Dr. J. Marion Sims in Montgomery, Alabama (Jan 2013)" by Richard Apple licensed under CC BY-SA 3.0
America's maternal mortality gap can be traced to slavery-era medical exploitation.
Black women are up to four times more likely to die due to pregnancy- and birth-related complications than their white counterparts. Among the reasons are a legacy of experiments on Black women by white doctors since the first Africans were brought here as chattel and racist assumptions that underpin gaps in cultural competency today.
“You have to consider the history and the context that the medical profession has been trained in over generations, and a lot of it is rooted in these racialized myths about Black people, especially with this idea of race as biology rather than race as a social construct,” said Keisha Bentley-Edwards, an associate professor at Duke University School of Medicine. “So with that, you can look at J. Marion Sims and his decision not to provide appropriate anesthesia to enslaved women [during surgery] along with Black people being perceived as not experiencing pain in...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...